A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. (Q34443946)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. |
scientific article |
Statements
A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors (English)
Branimir Sikic
Peter D Eisenberg
Georgy Manikhas
Rashmi Chugh
Matthew A Gubens
Robert J Stagg
Ann M Kapoun
Lu Xu
16 October 2014